121 filings
Page 5 of 7
8-K
6s5dtepl 9rx
28 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
26lo5372cf
15 Mar 18
Other Events
12:00am
8-K
5vuzcex48d98l8w0yny3
13 Mar 18
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
12:00am
8-K
0rdtywueli71tijwtm2x
7 Mar 18
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
12:00am
8-K
n2ao0r5mduwkrdik
7 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
snzjcb
8 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
pn6lcywkjxml 2x2
18 Dec 17
Entry into a Material Definitive Agreement
12:00am
8-K
atbav
7 Nov 17
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
g2e5 2lo06kftfi7g6j
3 Aug 17
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
poq4h99h
27 Jun 17
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
12:00am
8-K
jtfha1d6b8yx0 naxq8
2 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
e9uw3
9 May 17
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
m43imwplgug18t
26 Apr 17
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
12:00am
8-K
i0aikcmw
24 Mar 17
Other Events
12:00am
8-K
850qw0h3wu50
14 Mar 17
Departure of Directors or Certain Officers
12:00am
8-K
d4489ch ld8fywc4
9 Mar 17
Other Events
12:00am
8-K
18otm2e
8 Mar 17
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
12:00am
8-K
gp9 jryoa
3 Jan 17
Other Events
12:00am
8-K
4wtp3a6ql y7gn
3 Nov 16
Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
9g35r7xfpz fw1b8uyav
27 Sep 16
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
12:00am